Search Results 1461-1470 of 18152 for monoclonal antibody
... monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis. ... antibodies or molecules, antibody-drug conjugates (BCMA-ADC), or ...
Subject is naïve to treatment with ABBV-383 or anti-BCMA bispecific antibodies. ... Received a monoclonal antibody given with anti-neoplastic intent ≤30 days ...
small molecules and >30 mL/min for monoclonal antibodies unless otherwise specified in the Arm Specific Eligibility. These cut-off values may be modified ...
The purpose of this study is to determine the cellular and mechanistic basis of bone marrow hematopoietic dysfunction in untreated Monoclonal B Cell ...
... antibody;; Positive HCV antibody followed by positive confirmatory test (e.g., quantitative HCV RNA test). NOTE: Subjects with positive HBsAg or HBc antibody ...
SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells ...
the Second International Workshop on Waldenström macroglobulinemia. - At least 2 prior lines of treatment, including an anti-CD20 monoclonal antibody-containing ...
In 2004,. Mayo Clinic researchers discovered the antibody NMO-IgG — the first serum biomarker for any form of inflammatory demyelinating brain disease. A year ...
Recipients who, in the opinion of the investigator, are likely to require antibody-depletion therapy during trial participation. Antibody-depleting ...
... monoclonal antibody, including humanized or chimeric antibodies. Subject has known immediate or delayed hypersensitivity, intolerance or contraindication to ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift doubles in impact to help more patients.